Publication
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerThyroid Gland Papillary Carcinomacivic_curation1.00
- geneBRAFcivic_curation1.00
- geneTERTcivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantTERT C228Tcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25024077
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| (prognostic) | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID656In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=… (full text at CIViC) PMID 25024077 · Xing et al., 2014 · Open in CIViC | civic |
| TERT C228T1 | ||||||||
| (prognostic) | Thyroid Gland Papillary CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID655In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no muta… (full text at CIViC) PMID 25024077 · Xing et al., 2014 · Open in CIViC | civic |